Drug Profile
Research programme: isophosphoramide mustard analogues - Alaunos Therapeutics
Alternative Names: ZIO-202; ZIO-203Latest Information Update: 31 Jan 2022
Price :
$50
*
At a glance
- Originator Southern Research Institute
- Developer ZIOPHARM Oncology
- Class Phosphoramide mustards
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Jan 2022 ZIOPHARM Oncology is now called Alaunos Therapeutics
- 29 Sep 2005 ZIOPHARM merged with EasyWeb to form ZIOPHARM Oncology
- 11 Jan 2005 Preclinical trials in Cancer in USA (unspecified route)